Organogenesis Holdings Inc (ORGO) Receives a Buy from BTIG

By Carrie Williams

BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings Inc (ORGOResearch Report) yesterday and set a price target of $12. The company’s shares closed yesterday at $8.43, close to its 52-week low of $6.28.

Zimmerman said:

“Improved Cap Structure, ORGO $12 PT Organogenesis (ORGO) has been in the wound market since 1998, creating one of the largest pure-play wound care companies in the fast growing and underpenetrated Advanced Wound Care market. ORGO has built a ~$200M rev. business driven by a combo of stalwart wound products (Apligraf and Dermagraft) with faster growing PuraPly for early wound intervention. With an expansive portfolio and a significantly under- penetrated market opportunity (plus additional TAM outside of wound), ORGO has runway to grow. In addition, ORGO may be able to capture share from embattled competitors who may be struggling. Lastly, while reimbursement changes may hamper growth in one of ORGO’s products in late FY20, the combination of NPIs, a growing sales force, and clinical efficacy should mitigate reimbursement headwinds.”

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 35.0% and a 68.5% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Organogenesis Holdings Inc with a $12 average price target.

See today’s analyst top recommended stocks >>

Based on Organogenesis Holdings Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.26 million. In comparison, last year the company had a GAAP net loss of $1.09 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.